Budenofalk 2 mg rectal foam represents a major new option in the treatment of patients with ulcerous colitis
Authors:
M. Lukáš
Authors‘ workplace:
Klinické a výzkumné centrum pro střevní záněty, ISCARE a 1. LF UK v Praze a Ústav klinické biochemie a laboratorní diagnostiky, 1. LF UK v Praze
Published in:
Gastroent Hepatol 2012; 66(5): 413-414
Category:
Drug Profile
Sources
1. Brunner M, Vogelsang H, Greinwald R et al. Colonic spread and pharmacokinetics of budesonid foam in patients with mild to moderately active ulcerative colitis. Aliment Pharmacol Ther 2005; 22(5): 463–470.
2. Gross V, Ben-Meir S, Lavy A et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther 2006; 23(2): 303–312.
3. Travis SPL, Stange EF, Lémann M et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. JCC 2008; 2(1): 24–62.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
2012 Issue 5
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole vs. Tramadol in Postoperative Analgesia
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
- Safety and Tolerance of Metamizole in Postoperative Analgesia in Children
Most read in this issue
- Budenofalk 2 mg rectal foam represents a major new option in the treatment of patients with ulcerous colitis
- Epidemiology of malignant tumours of the gastrointestinal tract in the Czech Republic – state of the art and prediction
- Pancreatic cancer
- Prof. MUDr. Aleš Hep, CSc., turned 60